Vaccine plus Keytruda lowers relative risk of recurrence or death 42%

By Amara Osei

In a controlled study involving more than 1,100 patients with resected melanoma, an individualized tumor-mutation vaccine combined with Keytruda reduced the relative risk of recurrence or death by 42%. The same combination lowered the relative risk of distant metastasis (spread to another site) or death by 38%, according to trial results reported by Moderna and Merck.

The study compared two postoperative groups: vaccine plus Keytruda, and Keytruda plus placebo as control. It therefore tested an adjuvant strategy (treatment after surgery to reduce recurrence), not a vaccine intended to prevent melanoma from arising.

At two years, more than 82% of patients receiving vaccine plus Keytruda remained alive without disease recurrence, compared with 70% receiving Keytruda plus placebo. That difference exceeds 12 percentage points, but it cannot be translated into an absolute reduction in recurrence or death without the underlying event counts.

What did the trial actually demonstrate?

The reported signal was a 42% relative reduction in the combined outcome of disease recurrence or death. The report also gave a 38% relative reduction in distant metastasis or death. These are relative measures; although the summary supplies two-year percentages without recurrence, it omits absolute event risks, confidence intervals, and hazard ratios for both combined outcomes.

That distinction matters. A 42% relative reduction in recurrence or death cannot be interpreted as a 42% reduction in recurrence alone. Without separate numbers for recurrence and mortality, readers cannot determine how much benefit came from preventing recurrence, preventing death, or both.

The vaccine itself is the unusual component. It is created separately for each patient using the genetic mutations found in that individual’s tumor. UNN, citing Bild, said the treatment is intended to “teach” the immune system to recognize and destroy cancer cells.

That customization shifts part of the treatment challenge to finding tumor mutations and producing a matched product. The source does not describe turnaround time, manufacturing, quality control, or price, so practical feasibility remains unassessed.

How strong is the evidence?

The summary originated with Moderna and Merck, the American companies that reported the trials. Results were scheduled for presentation at the European Society for Medical Oncology congress in Madrid. The source does not identify a peer-reviewed publication or describe the study phase, randomization method, or masking.

Several clinically relevant details remain absent. The report gives no melanoma stage, tumor thickness, nodal status, or subgroup results. It also omits adverse events, treatment discontinuations, and follow-up beyond the two-year outcome, limiting assessment of benefit durability and safety.

Those omissions do not erase the reported signal, but they constrain how far the numbers can travel. The summary resembles a company announcement awaiting fuller scrutiny, rather than a complete evidence package from which practice can change.

The comparator also clarifies the result’s scope. Control patients received Keytruda, making the added intervention the personalized vaccine. The 82% and 70% figures therefore compare vaccine-augmented Keytruda with Keytruda plus placebo, not vaccine against no systemic treatment.

Is this a preventive skin-cancer vaccine?

UNN was explicit: “It is not a preventive cancer vaccine.” The intended population comprises patients whose melanoma has already been surgically removed, with the goal of preventing return or spread. No information in the report addresses vaccination to prevent a first melanoma diagnosis.

The treatment remains experimental and has not received approval for widespread use. That status applies to the personalized vaccine–Keytruda combination described here, and the report does not support adoption outside a study.

The next evidentiary milestone is the planned congress presentation in Madrid, which may clarify the absolute risks, trial design, and safety profile. Until those data appear, the 42% figure remains a preliminary company-reported result rather than a settled standard of care.